Bayard Clarkson

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

24h-index6.3kcitations59works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(18), Chronic Lymphocytic Leukemia Research(14), Acute Myeloid Leukemia Research(7), Acute Lymphoblastic Leukemia research(7), Neutropenia and Cancer Infections(5)

Publications59 total

Combination Therapy involving L-Asparaginase in Acute Leukemia1
Proceedings of the International Symposium on Comparative Leukemia Research·2015· 1 cited
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
Journal of Clinical Investigation·2007· 656 citedOpen Access
Synthesis and Biological Evaluation of a Fluorine-18 Derivative of Dasatinib
Journal of Medicinal Chemistry·2007· 38 citedOpen Access
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance
Proceedings of the National Academy of Sciences·2006· 108 citedOpen Access
Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors
Nuclear Medicine and Biology·2005· 13 cited
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
PubMed·2003· 66 cited
Gleevec inhibits β-amyloid production but not Notch cleavage
Proceedings of the National Academy of Sciences·2003· 195 citedOpen Access
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Cell·2003· 868 citedOpen Access
Role of p65(dok) in leukemogenesis by p210(bcr-abl)
Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory)·2000
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Science·2000· 1.8k cited
The phosphatidylinositol polyphosphate 5-phosphatase SHIP1 associates with the Dok1 phosphoprotein in Bcr-Abl transformed cells
Cellular Signalling·2000· 30 cited
Characterization of two novel sublines established from a human megakaryoblastic leukemia cell line transfected with p210BCR-ABL
Leukemia Research·2000· 10 cited
Response to SB Marley, JL Lewis, JM Goldman and MY Gordon
Leukemia·1998
Response to Michele Baccarani
Leukemia·1998
Specific genetic defects as targets for selective therapies. Commentary.
PubMed·1994
Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment.
PubMed·1993· 61 cited
Characterization of lineage-negative blast subpopulations derived from normal and chronic myelogenous leukemia bone marrows and determination of their responsiveness to human c-kit ligand.
PubMed·1993· 20 cited
Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype [see comments]
Blood·1991· 60 citedOpen Access
Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype [see comments]
Blood·1991· 69 citedOpen Access
Diffuse large cell lymphoma. Prognostic factors with treatment.
PubMed·1991· 15 cited
page 1 of 3Next →

Frequent Co-authors

Toby Gee(8), William G. Bornmann(7), Darren R. Veach(7), Ellin Berman(6), Sanford Kempin(5), Walter Lawrence(5), Janice Gabrilove(4), Ann A. Jakubowski(4), A Strife(4), Paul Clapp(4), John Grous(3), Katie Fain(3), Michael Andreeff(3), C Lambek(3), Z Arlin(3), B. J. Kennedy(3), W. Todd Miller(2), John Kuriyan(2), Howard I. Scher(2), Alan Yagoda(2)